Vaxcyte IncFRA Vaxcyte Stock Report

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. The company is headquartered in San Carlos, California and currently employs 158 full-time employees. The company went IPO on 2020-06-12. The Company’s pipeline includes pneumococcal conjugate vaccine (PCV), VAX-24, VAX-XP, VAX-A1 and VAX-PG. The Company’s PCV candidates is in development, targeting global pneumococcal vaccine market. The Company’s lead vaccine candidate, VAX-24, is a 24-valent, broad-spectrum investigational PCV being developed for the prevention of invasive pneumococcal disease (IPD) and pneumonia. The Company’s PCV candidate, VAX-XP, leverages its scalable and modular platform and builds on the technical proof-of-concept established by VAX-24. VAX-A1 is a novel conjugate vaccine candidate designed to prevent Group A Strep pervasive disease. VAX-PG is a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis and chronic oral inflammatory disease.